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In ThIs Issue
•	 Alectinib salvages Cns 
Relapses in ALK-Positive 
Lung Cancer Patients 
PreviouslyTreated with 
Crizotinib and Ceritinib
This brief report described the treatment with the 
next-generation anaplastic lymphoma kinase (ALK) 
inhibitor alectinib in 4 ALK-positive non–small-cell 
lung cancer (NSCLC) patients with leptomeningeal 
metastases (LM), who had both prior crizotinib and 
ceritinib treatments. In this series, alectinib was given 
at a starting dose of 600 mg twice daily, via single-
patient, compassionate use protocols at two institutions. 
Significant clinical and radiographic improvements in 
LM were found in three out of four patients treated with 
alectinib. Stable intracranial disease was observed in the 
fourth patient for 4 months before disease progression. 
This study demonstrated that alectinib is active in 
ALK-positive NSCLC patients with LM, despite 
prior exposure to both crizotinib and ceritinib. Further 
prospective studies of alectinib in ALK-positive patients 
with LM are warranted. Clinical trials evaluating novel 
ALK inhibitors, for instance those rationally designed 
to minimize drug efflux and optimize CNS penetration, 
should include CNS-specific cohorts and/or prospective 
assessment of intracranial response. (p. 232)
In ThIs Issue
•	 The Impact of Thymoma 
histotype on Prognosis in 
a Worldwide Database
This study examined 4221 thymomas with World 
Health Organization histotype information along with 
the demographic and geographic distribution from 
the International Thymic Malignancy Interest Group 
retrospective database, and analyzed the association 
of thymoma histotypes with survival and recurrence. 
One of the new findings was geographic differences, 
for instance a lower incidence of type A and B2 
thymoma in Asia. The most common type is B2 (28%), 
whereas the least common one is A (12%), with B2 
significantly more frequent in Europe and the US. No 
differences are found in sex distribution. Older age is 
significantly associated with type A and AB (64 and 
57 years, respectively). Early stage is observed in type 
A (90% stages I–II) and AB versus B1 to B3 (38% 
B3 are stage III). Univariate analysis showed that 
stage I/II tumors of type A and AB have significantly 
lower recurrence (1–2%) versus B1 to B3 (2–7%). 
Multivariate analysis demonstrated that age, stage, and 
resection status are the greatest independent prognostic 
factors in survival and recurrence, whereas histology is 
an independent prognostic factor in recurrence but not 
survival for stages I and II in type AB versus B1, B2, 
and B3. (p. 367)
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The authors sought to evaluate the prognostic 
significance of adenocarcinoma histology and to 
develop a prognostic nomogram for postsurgical 
patients with synchronous multiple non–small-cell 
lung cancers involving multiple lobes. They conducted 
a pooled analysis of six datasets that included 467 
patients without extra-thoracic metastasis, who had 
resected synchronous lung cancers in multiple lobes. 
The data showed that 54.2% of patients had solely 
adenocarcinoma histology, in which a better median 
survival was observed versus their counterparts (67.4 
versus 36.2 months; p < 0.001). Multivariate analysis 
also demonstrated bearing exclusively adenocarcinoma 
histology is an independent predictor of a better survival 
(hazard ratio, 0.61). Other survival predictors include 
N0, T-size less than or equal to 3 cm, bilateral cancers, 
age less than 70 years, and women. They developed 
a nomogram incorporating these factors, which was 
well calibrated with a moderate to good discrimination 
(Harrell C-statistic, 0.70), could be used to predict 
survival with acceptable accuracy. The findings revealed 
the prognostic significance of a few characteristics in 
this patient population, particularly the presence of 
exclusively adenocarcinoma histology that correlates 
with good prognosis. This could be useful in clinical 
decision making and future studies. (p. 338)
•	 Prognostic nomogram 
to Predict survival After 
surgery for synchronous 
Multiple Lung Cancers in 
Multiple Lobes
•	 endobronchial ultrasound 
Versus Mediastinoscopy 
for Mediastinal nodal 
staging of non–small-Cell 
Lung Cancer
This prospective trial compares the diagnostic 
performance of endobronchial ultrasound-guided 
transbronchial needle aspiration (EBUS-TBNA) to 
that of mediastinoscopy in patients with non–small-
cell lung cancer (NSCLC). Eligible patients had 
histologically proven NSCLC and suspicious N1, N2, or 
N3 metastasis. EBUS-TBNA was given to 138 patients, 
whereas both EBUS-TBNA and mediastinoscopy 
were given to 127 patients. N2/N3 disease was found 
in 59.1% of the patients. The diagnostic sensitivity, 
specificity, accuracy, positive predictive value, and 
negative predictive value (NPV) of EBUS-TBNA 
on a per-person analysis were 88.0%, 100%, 92.9%, 
100%, and 85.2%, respectively, whereas those of 
mediastinoscopy were 81.3%, 100%, 89.0%, 100%, and 
78.8%, respectively. There were significant differences 
between EBUS-TBNA and mediastinoscopy in 
sensitivity, accuracy, and NPV (p < 0.005). The authors 
concluded that the diagnostic performance of EBUS-
TBNA was superior to mediastinoscopy for mediastinal 
staging of cN1–3 NSCLC. EBUS-TBNA should be the 
first-line procedure in this patient population because of 
its superior sensitivity and being less invasive. (p. 331)
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of these samples were also included in the analysis. The 
analysis found that only women harbored the EGFR exon 
19 deletions, of which black women had higher odds 
versus white women (odds ratio = 3.914; p = 0.048).. 
Histology-associated differences in mutation frequencies 
were also observed, where higher numbers and diversity 
of mutations (often co-occurring mutations) were found 
in adenocarcinomas than in squamous cell carcinomas. 
This study also reported for the first time the discovery 
of DDR2 variants (DDR2 p.G505S and DDR2 p.L63V) 
in both normal and NSCLC tissues from patients. Taken 
together, this study revealed novel findings associating 
race with molecular diversity in NSCLC patients, 
indicating the need for further molecular studies in diverse 
NSCLC patient populations. In addition, the discovery 
of the DDR2 variants underscores the importance of 
inherited alleles and warrants further evaluation of their 
occurrence and oncogenic role in NSCLC. (p. 250)
ReseARCh WATCh
•	 Lobectomy, sublobar 
Resection, and stereotactic 
Ablative Radiotherapy for 
early stage non–small-
Cell Lung Cancers in the 
elderly
The authors assessed and compared clinical 
characteristics and survival outcomes in 9093 
elderly patients with early stage NSCLC treated with 
lobectomy, sublobar resection, or stereotactic ablative 
radiotherapy (SABR). The analysis of Medicare data 
in the Surveillance, Epidemiology, and End Results 
database showed that lobectomy was performed in 
79.3% of the patients, sublobar resection in 16.5%, and 
SABR in 4.2%. Worse overall survival (OS; adjusted 
hazard ratio [AHR], 1.32; p < 0.001) and lung cancer-
specific survival (AHR, 1.46; p < 0.001) were observed 
in the sublobar resection group compared with the 
lobectomy group. Similar results were obtained in 
propensity score-matching analysis. The SABR group 
showed better OS than the lobectomy group in the first 
6 months after diagnosis (AHR, 0.46; p < 0.001) but 
worse OS afterwards (AHR, 1.66; p < 0.001). Similar 
OS was observed in both groups in the propensity score-
match analysis (AHR, 1.01; p = 0.94). The findings 
support lobectomy as the optimal treatment for elderly 
patients with early stage NSCLC. Patients with very 
advanced age and multiple comorbidities could opt 
for SABR which offers lower risk of periprocedural 
mortality and long-term survival.
Shirvani SM, Jiang J, Chang JY, et al. Lobectomy, 
sublobar resection, and stereotactic ablative 
radiotherapy for early-stage non–small cell lung 
cancers in the elderly. JAMA Surg 2014. doi:10.1001/
jamasurg.2014.556.
•	 Racial Diversity of 
Actionable Mutations 
in non–small-Cell Lung 
Cancer
The authors aimed to determine the underlying cause for racial 
discrepancy among non–small-cell lung cancer (NSCLC) patients, in 
particular, the differential incidence of somatic cancer gene mutations. 
Samples from NSCLC patients (335 white and 137 black) were 
analyzed using a MALDI-TOF mass-spectrometry for 214 coding 
mutations in 26 known cancer genes. Paired normal DNA for 299 
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•	 Active and Passive 
smoking in Relation to 
Lung Cancer Incidence 
in the Women’s health 
Initiative Observational 
study Prospective Cohort
risk in never-smokers with any passive exposure to 
smoking (childhood, adult home and work). Never-
smokers with adult home passive exposure to smoking 
of greater than 30 years did show a trend of increasing 
risk compared with never-smokers without such 
exposure (HR, 1.61). Taken together, this cohort showed 
that active smoking is associated with higher risk of 
all lung cancer subtypes, and significantly higher risk 
was found in current than ex-smokers. Never-smokers 
with long passive adult home exposure to smoking have 
the tendency to have increased lung cancer risk. The 
findings reflected the importance of development and 
implementation of smoking prevention and cessation 
strategies as well as research on non-smoking-related 
lung cancer risk factors.
Wang A, Kubo J, Luo J, et al. Active and passive 
smoking in relation to lung cancer incidence in the 
Women’s Health Initiative Observational Study 
prospective cohort. Ann Oncol 2014. doi:10.1093/
annonc/mdu470.
This prospective cohort study conducted across 40 US centers 
aimed to assess the association between lung cancer incidence 
and both active and passive smoking in 76,304 postmenopausal 
women (multi-ethnic, aged 50–79 years). Of the 901 lung cancer 
cases identified in a median of 10.5 years of follow-up, current- 
and ex-smokers had higher lung cancer incidence compared with 
never-smokers (hazard ratios [HR], 13.44 and 4.20, respectively). 
Significantly higher risk was observed in current-smokers for 
non–small-cell lung cancer (odd ratio [OR], 12.05) and small-
cell lung cancer (OR, 100.84) versus never-smokers (p < 0.0001). 
Similar results, though lower OR than current-smokers, were found 
in ex-smokers. There was no significant increase in lung cancer 
I1171T mutation) were identified to cause resistance to 
alectinib and crizotinib but were sensitive to ceritinib 
and other next-generation ALK inhibitors. Patient who 
acquired resistance to alectinib and were treated with 
ceritinib showed marked response lasted for 7 months. 
Simulation study indicated ALK structural modifications 
by both mutations which led to reduced binding affinity 
for alectinib. All in all, the results identified two new 
ALK mutations and demonstrated the ability of ceritinib 
to tackle resistance to alectinib, suggesting its potential 
use in sequential treatment with other next-generation 
ALK inhibitors.
Katayama R, Friboulet L, Koike S, et al. Two novel 
ALK mutations mediate acquired resistance to the next-
generation ALK inhibitor alectinib. Clin Cancer Res 
2014. doi:10.1158/1078-0432.ccr-14–1511.
•	 study Identifies Two novel 
ALK Mutations Causing 
Lung Cancer Resistance to 
ALK Inhibitors
The authors are interested in dissecting the mechanism of resistance 
to the next-generation ALK inhibitor alectinib and determine 
alternatives to tackle this resistance for patients with ALK-positive 
non–small-cell lung cancer (NSCLC). They analyzed alectinib 
resistance in a cell line model and a resistant patient tumor sample. 
The potency of other next-generation ALK inhibitors were assessed 
in Ba/F3 models with alectinib-resistant ALK mutations. Ceritinib 
was tested in the patient resistant to alectinib for its efficacy. 
Computational thermodynamic simulation with MP-CAFEE was 
used to study the structure–activity relationships of ALK mutations. 
Two novel ALK mutations (V1180L gatekeeper mutation and 
hazard ratio [HR], 0.45; p < 0.001). Significantly better 
objective response rates were also achieved in the 
crizotinib arm (74% versus 45%; p < 0.001). Median 
overall survival was not reached in either arm (HR, 
0.82; p = 0.36). The crizotinib arm exhibited greater 
reduction in lung cancer symptoms and more improved 
quality of life when compared with the chemotherapy 
arm. The authors concluded that crizotinib as first-line 
treatment was superior to standard first-line pemetrexed 
+ platinum chemotherapy in this patient population.
Solomon BJ, Mok T, Kim D-W, et al. First-line 
crizotinib versus chemotherapy in ALK-positive lung 
cancer. N Engl J Med 2014;371:2167–2177.
•	 First-Line Crizotinib Versus 
Chemotherapy In ALK-
Positive Lung Cancer
PROFILE 1014, an open-label, randomized phase III trial, aimed 
to compare first-line crizotinib with standard chemotherapy 
in 343 patients with advanced ALK-positive nonsquamous 
non–small-cell lung cancer (NSCLC), with no prior systemic 
treatment. The primary end point, progression-free survival 
(PFS), was significantly improved in the crizotinib arm versus 
the chemotherapy arm (median, 10.9 months versus 7.0 months; 
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•	 Patient-Derived Models of 
Acquired Resistance Can 
Identify effective Drug 
Combinations for Cancer
MEK inhibitors were effective in ALK-positive-resistant 
tumor harboring MAP2K1 activating mutation, EGFR 
+ FGFR inhibitors were active in an EGFR mutant-
resistant tumor bearing a novel FGFR3 mutation, and 
ALK + SRC inhibitors were effective in multiple ALK-
driven models. This model, with further optimization, 
could be valuable in guiding treatment decisions for 
personalized lung cancer therapy.
Crystal AS, Shaw AT, Sequist LV, et al. Patient-
derived models of acquired resistance can identify 
effective drug combinations for cancer. Science 2014. 
doi:10.1126/science.1254721.
The authors set out to establish a pharmacogenomics model to 
facilitate the discovery of drug combinations that will tackle 
resistance. Cell lines were derived from biopsies of lung cancer 
patients resistant to EGFR or ALK inhibitors and subsequently 
subjected to genetic analyses and a pharmacological screen. They 
identified multiple effective drug combinations, such as ALK + 
undiscounted life years (LYs) saved; and quality-
adjusted life years (QALYs) gained by TIPS. The results 
showed that about 179,099 QALYs were saved and 
17,109 premature deaths in the US were averted. TIPS 
spent approximately $48 million for the campaign, 
which attributed to about $480 per quitter, $2,819 per 
premature death prevented, $393 per LY saved, and 
$268 per QALY gained. To conclude, TIPS was both 
successful at cutting smoking-attributable morbidity and 
mortality, and was very cost–effective compared with 
any lung cancer prevention effort.
Xu X, Alexander RL Jr, Simpson SA, et al. A 
cost–effectiveness analysis of the first federally 
funded antismoking campaign. Am J Prev Med 2014. 
doi:10.1016/j.amepre.2014.10.011.
•	 A Cost–effectiveness 
Analysis of the First 
Federally Funded 
Antismoking Campaign
This study assessed the cost–effectiveness of the first federally 
funded antismoking campaign (Tips From Former Smokers 
[TIPS]) launched by CDC in 2012, which generated a 12% relative 
increase in smoking cessation attempts at the population level. The 
analysis estimated sustained cessations; premature deaths averted; 
•	 Determinants and 
Prevalence of e-Cigarette 
use Throughout the 
european union: A 
secondary Analysis of 
26,566 Youth and Adults 
from 27 Countries
4.7% of ex-smokers, and 1.2% of never-smokers in the 
EU have ever used an e-cigarette. Ever users tend to be 
younger (15–24 year olds, adjusted odd ratio [aOR], 
3.13; 25–39 years old, aOR, 2.00), current-smokers 
(6–10 cigarettes/day, aOR 1.53; or 11–20 cigarettes/day, 
aOR 2.07), or past-year quit attempters (aOR, 2.08). 
Ex-smokers who have ever used an e-cigarette tend to be 
younger. All in all, the findings highlighted the need to 
understand the potential long-term effect of e-cigarette 
use on individual health, cessation, and nicotine 
addiction. Development of a European framework to 
regulate e-cigarette within the revised EU Tobacco 
Product Directive is also warranted.
Vardavas CI, Filippidis FT, Agaku IT. Determinants 
and prevalence of e-cigarette use throughout the 
European Union: A secondary analysis of 26 566 youth 
and adults from 27 Countries. Tobacco Control 2014. 
doi:10.1136/tobaccocontrol-2013–051394.
This study evaluated the prevalence and determinants of e-cigarette 
use among 26,566 individuals aged greater than or equal to 
15years in 27 European Union (EU) member countries during 
2012, of which 7352 were current cigarette smokers and 5782 were 
ex-smokers. The results showed that 20.3% of current-smokers, 
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neWs In BRIeF
•	 study shows Wide 
Variations in Global 
Cancer survival Rates
The CONCORD-2 study of global cancer survival, 
published in The Lancet, reported persistent poor 
outcomes in lung and liver cancers across the globe, 
both with 5-year survival of less than 20% in Europe, 
15–19% in North America, and 7–9% in Mongolia and 
Thailand. On the other hand, 5-year survival rates in 
colon, rectal, and breast cancers have improved steadily 
in most developed countries, with greater than or equal 
to 60% in colon and rectal cancer across 22 countries, 
and greater than or equal to 85% in breast cancer across 
17 countries. Wide variations in 5-year survival were 
observed in many cancers, including leukemia, prostate, 
and cervical cancers. This study included records of 
cancer diagnosis between 1995 and 2009, submitted by 
279 population-based cancer registries in 67 countries.
•	 Aplcc 2014: Managing 
Lung Cancer in the Limited 
Resource Countries
Soe Aung from Myanmar also pointed out that 
international guidelines such as those established 
by NCCN, ASCO, and ESMO especially for the 
management of metastatic cancers are not always 
appropriate in the low and middle income countries. He 
discussed about the underlying reasons including few 
up-to-par pathological facilities, poor imaging facilities, 
lack of effective health care policies, cultural taboos and 
social stigma, wide gap between urban and rural areas 
in access to oncology care, inadequate expertise, scarce 
therapeutic resources, and lack of multidisciplinary 
management strategies. He reviewed the management 
of all lung cancer patients treated at the Yangon General 
Hospital Oncology Center (n = 561) from 2003 to 2006, 
and concluded that pragmatic approach instead of the 
recommended guidelines is most of the time required in 
resource limited regions.
Last but not least, Unchalee Permsuwan from 
Thailand talked about incorporation of economic 
evaluation in lung cancer management within a limited 
budget. These include cost–benefit analysis, cost-
minimization, cost–effectiveness analysis, and cost-utility 
analysis. Issues to be addressed in such evaluations 
include comparators, type of evaluation, measuring costs 
and outcomes, time horizon, and sensitivity analysis. 
It could be achieved by well-designed randomized 
controlled study or modeling-based strategy.
Many low and middle income countries in the Asia Pacific region 
have resource constraints for health care and lung cancer. During 
this concurrent session of the 2014 IASLC Asia Pacific Lung 
Cancer Conference (APLCC) in Kuala Lumpur, Malaysia, Sudsawat 
Laohavinij from Thailand discussed four major strategies employed 
in Thailand to overcome funding limitations—(1) Capitation of 
outpatient payment for their health care programs that cover the 
majority of the population; (2) Use of diagnosis-related groups 
for inpatient payment in all health insurance schemes; (3) Cost–
effectiveness by having a national list of essential medicine and 
treatment protocols for 11 common cancers for reimbursement, 
restrictions with very high cost/new drugs that require 
predetermined medical criteria and preauthorization; and (4) Use of 
quality controlled generic drugs and price negotiation.
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•	 APLCC 2014: Lung Cancer 
in the era of Molecular 
Diagnosis and Targeted 
Treatment
of Asian patients with advanced NSCLC harboring 
common EGFR mutations (Del19/L858R) treated with 
afatinib versus chemotherapy. They found that first-line 
afatinib significantly improved OS versus chemotherapy 
(Hazard ratio [HR], 0.82; p = 0.083) in Asian 
NSCLC patients harboring common EGFR mutation, 
particularly patients with Del19 (31.7 versus 21.1 
months; HR, 0.61; p = 0.001), not those with L858R 
(HR, 1.25; p = 0.191). Another study presented by Tony 
Mok et al., KEYNOTE-042 (Abstract A-0235), is an 
ongoing open-label, phase III trial of pembrolizumab 
(MK-3475, anti-PD-1 antibody) versus platinum doublet 
chemotherapy as first-line therapy for PD-L1 positive, 
EGFR wild-type and ALK-negative advanced NSCLC 
patients. Enrollment is expected to begin in November 
2014. The study is expected to provide data on the 
safety and efficacy of pembrolizumab 200 mg Q3W 
versus chemotherapy.
Silvia Novello from Italy discussed early diagnosis 
of lung cancer, in particular low-dose CT (LDCT) 
screening as a result of the National Lung Cancer 
Screening Trial (NLST), in her plenary talk. The study 
showed a 20% reduction of lung cancer mortality using 
LDCT versus chest X-ray, though with some concerns 
regarding high false positive rate (96%), overdiagnosis 
(19% with 7 years of follow-up and 9% with lifetime 
follow-up), radiation exposure, cost–effectiveness, 
and implementation in clinical practice. The NELSON 
trial is assessing a nodule management protocol based 
on volumetry and volume doubling time in lowering 
the false positive rate. The study by Pyenson et al. 
demonstrated cost–effectiveness with lung cancer 
screening in high risk individuals in the US although 
institutions are not convinced yet.
Natthaya Triphuridet from Thailand also discussed 
the cost–effectiveness analyses and challenges of LDCT 
screening. The outcomes of the analyses varied widely. 
Integration of smoking cessation interventions into 
screening program was shown to improve the cost–
effectiveness of lung cancer screening. Other issues 
to address include evaluation of the benefits of LDCT 
screening in Asian population and endemic area of 
Tuberculosis, and identification of promising alternative 
screening modalities, for instance digital tomosynthesis 
(DT) with comparable sensitivity and diagnostic 
accuracy as LDCT but a much lower radiation dose, cost 
and reading time than CT.
On the subject of outcomes of patients with advanced NSCLC 
during the plenary sessions, Yoichi Nakanishi from Japan 
emphasized the importance of ethnic difference in lung cancer 
treatments. Better prognoses have been observed in Japanese 
lung cancer patients versus those of Caucasian patients regardless 
of disease stages, according to a nation-wide registry study in 
Japan. Five-year survival rates among 14,695 newly diagnosed 
Japanese lung cancer patients in 2002 were 66% for surgery, 
13.3% for radiotherapy, and 6.5% for drug therapy. Platinum-
based doublet therapy in metastatic NSCLC generated survival of 
about 9 months in western countries, but 13–14 months in Japan. 
Survival of greater than 24 months is achieved today with EGFR 
TKI therapy on a patient harboring the EGFR mutation. The 
disparity in prognosis would be attributed in part by the difference 
in distribution, e.g., of the EGFR mutation between Asian patients 
(30–40%) and Caucasian patients (8%) with NSCLC. The Japanese 
clinical practice guidelines recommended biomarker testing for, 
e.g., EGFR mutation, EML4-ALK fusion and uridine diphosphate 
glucuronosylytansferase (UGT 1A1), which were covered by the 
national health care program and therefore allowing access to most 
eligible lung cancer patients.
Sumitra Thongprasert from Thailand also pointed out that 
the improvement of patient outcomes in developing Asia Pacific 
countries is not as high as those in developed countries in the 
region. She mentioned the high cost of new therapies as one of the 
challenges in selecting optimal treatment for patients, particularly in 
resource-limited setting.
In his plenary talk on personalized targeted therapy for 
advanced lung cancer, Tony Mok gave an account on the progress 
of lung cancer treatment from chemotherapy to targeting EGFR, 
ALK, ROS, PD-L1, and others on the horizon. In a relevant study 
presented by Wu et al. (Abstract A-0142), data from two large 
open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 
6 [LL6]) were combined to compare the overall survival (OS) 
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•	 study Finds Potential 
Predictive Biomarker for 
Treatment with Anti-Pd-L1 
Antibody Mpdl3280a in 
Cancer Patients
In a letter to Nature, Herbst et al. reported that 
PD-L1 inhibition using the anti-PD-L1 antibody, 
MPDL3280A in advanced non–small-cell lung 
cancer (NSCLC), melanoma and other cancers 
among 175 patients showed marked responses (18% 
by RECIST response criteria) across cancer types, 
with rapid response in some patients, and durable 
responses in almost all responders (esp. NSCLC 
patients). Assessment of pretreatment biopsies showed 
significant correlation of response with PD-L1 
expression in tumor-infiltrating immune cells, but 
not in tumor cells: overall (p = 0.007) and NSCLC 
(p = 0.015). The responses were correlated with 
expression of T-helper type 1 gene and CTLA4, and 
the absence of fractalkine (CX3CL1) in pretreatment 
tumor samples. Examination of on-treatment biopsies 
revealed no increase in PD-L1 levels in tumor cells 
or tumor-infiltrating immune cells in responders. 
The treatment was generally well tolerated, with 
few severe side effects. The results suggest that the 
antibody MPDL3280A is most effective in patients 
with pre-existing immune response blocked by PD-L1, 
and reinvigorated upon MPDL3280A treatment. 
High level of PD-L1 in tumor-infiltrating cells could 
be potential predictive biomarker of response to 
anti-PD-L1 therapy in these patients if confirmed by 
further studies.
Image credit: NCI
neWs FROM The 
IAsLC TOBACCO 
COnTROL 
COMMITTee
•	 smoking Rates Fall in us 
Adults
Reuters reports on declines in smoking rates in US 
adults, based on a CDC report released in November. 
The Reuters report summarizes the statistics:
•  17.8% of American adults smoked cigarettes in 
2013, compared with
•  20.9% in 2005 and 42.4% in 1965
•  average daily cigarette consumption fell in 2013 to 
14.2 cigarettes from 16.7 in 2005
•  a fall in the rate of smoking every day in current-
smokers from 80.8% in 2005 to 76.9% in 2013
•  an increase in the proportion of smokers who smoke 
less than 10 cigarettes per day (16.4% in 2005 to 
23.3% in 2013)
•  the use of e-cigarettes by high school students in 
2013 was only 4.5%, however, this was a threefold 
increase from 2011.
You can find the Reuters report at www.reuters.com 
by typing “cigarette smoking by US smokers” in 
Search. The CDC report is at www.cdc.gov/media/
releases/2014/p1126-adult-smoking.html.
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China: A report from the New York Times (see link 
below) looks at proposed tobacco regulations from the 
Chinese government. We have to rely on the reporter’s 
analysis (if you do not read Mandarin) as the links 
provided do not easily lead to an English-language page. 
However, as reported, the proposals include bans on 
indoor public place smoking, on smoking in outdoor 
areas such as bus stops and sports venues and separate 
smoking areas in parks. There would also be restrictions 
on tobacco advertising (possibly even in schools!) and 
more warnings on packaging.
Russia: In Russia, the St Petersburg Times reports 
on a letter from Russia’s largest tobacco companies 
to President Putin opposing parliamentary moves to 
impose a minimum price on tobacco products. The 
authenticity of the letter is questioned in the report (with 
the citing newspaper Vedomosti, a business daily, was 
unable to confirm the letter) but the facts presented are 
that of a significant price increase for locally produced 
cigarettes in a country with a quoted smoking rate of 
60% for men and 25% for women. The locally produced 
cigarettes make up 40% of cigarettes sold in Russia 
and are currently less than 80% the cost of foreign 
brands. The proposed price increase would narrow 
that price gap. The tensions described tell us again of 
the complexities and difficulties of sustained, effective 
tobacco control.
http://sinosphere.blogs.nytimes.com/2014/11/25/
antismoking-regulations-seek-to-change-face-of-
china/?_r=1
http://sptimes.ru/index_bp.php?action_id=2&story_
id=41064&section=70
•	 China And Russia Propose 
Measures to Curb Tobacco 
use
